Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Category: #health  By Pankaj Singh  Date: 2019-10-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatment, adults on the other hand are required to take medication for bleeding. However, various pharmaceutical companies are still focusing on developing an effective treatment that can eliminate ITP in a short span of time.

Principia Biopharma Inc. is one such firm that has made some significant contribution in this field. The company has recently revealed preliminary data from its ongoing Phase 1/2 study of PRN1008, in a highly refractory and treatment-resistant patient population that are suffering from immune thrombocytopenia (ITP). 

Speaking on the development, Dolca Thomas, MD, Chief Medical Officer, Principia, said that the company is thrilled by the data presented and is delighted to see the scientific community recognizing this as a significant new clinical data from its oral BTK inhibitor. 

Thomas added that the company is looking forward towards sharing its findings at the oral presentation in ASH to the global hematology community.

Reportedly, in the preliminary data conducted on 15 patients who had finished a minimum of 12 weeks of therapy, greater response rate of more than 50% was witnessed in both the endpoints. Additionally, PRN1008 is claimed to be well-tolerated in all studies, which showed no episodes of thrombotic or bleeding events.

However, these earlier findings might change as more new patients will be progressed and enrolled in the study. Principia Biopharma is also likely to demonstrate an updated data at the forthcoming ASH (American Society of Hematology) Annual Meeting which will be conducted in December.

Incidentally, Principia Biopharma has also prior made headlines when it announced that it would be appointing former Chief Commercial Officer of Kite Pharma, Shawn Tomasello in its Board of Directors

As per Martin Babler, President and Chief Executive Officer, Principia Biopharma, the company is delighted to welcome Shawn in its Board as she brings in a good track record in commercializing and development of pharmaceutical products.

Source Credit: https://ir.principiabio.com/news-releases/news-release-details/principia-announces-positive-preliminary-data-prn1008-immune



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...